Novo Nordisk has confirmed that it is terminating the employment of newly hired individuals who have not yet commenced their roles within the company. This decision follows the implementation of a global freeze on new hires deemed not critically necessary for the company’s operations.

The pharmaceutical giant acknowledged the situation in response to inquiries from multiple media outlets.

The hiring freeze, designed to achieve savings and efficiencies within the organization, has unfortunately impacted a number of new hires in Denmark who had already received job offers but had not yet started working.

Novo Nordisk expressed regret for the difficult situation and uncertainty caused to the affected candidates.

As compensation, the company will provide one month’s salary in addition to the notice period to those whose job offers have been rescinded. However, Novo Nordisk has declined to disclose the exact number of individuals affected by this measure.

Company leadership had previously signaled the need for cost-cutting measures. The new CEO, Mike Doustdar, mentioned “savings and efficiencies” would be pursued in “less important areas,” while the former CEO, Lars Fruergaard Jørgensen, suggested potential layoffs during his departure announcement.